Abiopharma

PERSPECTIVE THERAPEUTICS, INC. (CATX)

Symbol	CATX
Name	PERSPECTIVE THERAPEUTICS, INC.
Sector	HEALTH CARE
Region	North America
Industry	Medical/Dental Instruments
Address	350 HILLS STREET,SUITE 106, RICHLAND, Washington, 99354, United States
Telephone	+1 509 375-5329
Fax	—
Email	—
Website	https://www.perspectivetherapeutics.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0000728387
Description	Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company. The Company is engaged in the advancement of treatment applications for cancers throughout the body. It is a producer of Cesium-131 brachytherapy seeds. These seeds are designed to treat a variety of cancers including prostate cancer, head and neck, lung and brain. The Company has also developed a lead-212 generator to secure isotope supply for clinical trials and commercial operations. Its lead-212 generator utilizes the isotope lead-212 to deliver alpha radiation specifically to cancer cells via specialized targeting peptides. The Company is also engaged in the development of imaging diagnostics (Pb-203 (Lead-203)). The Companys melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are under Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at various academic institutions. Additional info from NASDAQ: Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company. The Company is engaged in the advancement of treatment applications for cancers throughout the body. It is a producer of Cesium-131 brachytherapy seeds. These seeds are designed to treat a variety of cancers including prostate cancer, head and neck, lung and brain. The Company has also developed a lead-212 generator to secure isotope supply for clinical trials and commercial operations. Its lead-212 generator utilizes the isotope lead-212 to deliver alpha radiation specifically to cancer cells via specialized targeting peptides. The Company is also engaged in the development of imaging diagnostics (Pb-203 (Lead-203)). The Companys melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are under Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at various academic institutions.

2026-09-14 10:16

Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors

2026-09-11 10:00

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026

2026-09-08 21:16

(99% Neutral) PERSPECTIVE THERAPEUTICS, INC. (CATX) Files Form 8-K

2026-09-04 20:58

Lantheus Alpha Therapy, LLC 🔴 sold 113.9K shares of Perspective Therapeutics, Inc. (CATX) at $3.14 Transaction Date: Aug 31, 2026 | Filing ID: 000314

2026-09-04 17:49

New Form SCHEDULE 13D/A - Perspective Therapeutics, Inc. Filed: 2026-09-04 AccNo: 0001193125-26-383775 Size: 316 KB

2026-09-03 20:54

Lantheus Holdings, Inc. 🔴 sold 35.8K shares of Perspective Therapeutics, Inc. (CATX) at $3.12 Transaction Date: Sep 01, 2026 | Filing ID: 000310

2026-09-02 20:36

Lantheus Holdings, Inc. 🔴 sold 78.1K shares of Perspective Therapeutics, Inc. (CATX) at $3.14 Transaction Date: Aug 31, 2026 | Filing ID: 000308

2026-08-13 20:59

New Form SCHEDULE 13G/A - Perspective Therapeutics, Inc. Filed: 2026-08-13 AccNo: 0001104659-26-096145 Size: 19 KB

2026-08-10 20:22

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results

2026-08-07 11:43

New Form SCHEDULE 13G - Perspective Therapeutics, Inc. Filed: 2026-08-07 AccNo: 0000093751-26-000524 Size: 8 KB

Trial ID	Title	Phase	Indication	Status	Start Date	Completion Date	Source
NCT06710756	Lead-212 PSV359 Therapy for Patients With Solid Tumors	Phase1	Pancreatic Ductal Adenocarcinoma	Recruiting	2025-04-28	2032-05-28	ClinicalTrials.gov
NCT06148636	A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors	Early_Phase1	Neuroendocrine Tumors	Active_Not_Recruiting	2023-11-10	2027-12-31	ClinicalTrials.gov
NCT05636618	Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR…	Phase1	Neuroendocrine Tumors Unresectable	Recruiting	2023-09-27	2029-12-26	ClinicalTrials.gov
NCT05655312	MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Niv…	Phase1	Recurrent Melanoma (Skin)	Recruiting	2023-06-01	2029-12-31	ClinicalTrials.gov
NCT05111509	A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent	Early_Phase1	Neuroendocrine Tumor Grade 2	Active_Not_Recruiting	2022-08-22	2026-06-30	ClinicalTrials.gov
NCT04904120	Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy	Phase1	Melanoma (Skin)	Completed	2021-03-05	2022-09-20	ClinicalTrials.gov

Total clinical trials: 6

Product Name	Type	Development Stage	Therapeutic Area	Study Status	Trial ID
[212Pb]Pb-PSV359	Other	Phase PHASE1	Pancreatic Ductal Adenocarcinoma	RECRUITING	NCT06710756
[203Pb]Pb-PSV359	Other	Phase PHASE1	Pancreatic Ductal Adenocarcinoma	RECRUITING	NCT06710756
Nivolumab	Other	Phase PHASE1	Recurrent Melanoma (Skin)	RECRUITING	NCT05655312
[212Pb]VMT01	Other	Phase PHASE1	Recurrent Melanoma (Skin)	RECRUITING	NCT05655312
[203Pb]VMT01	Other	Phase PHASE1	Recurrent Melanoma (Skin)	RECRUITING	NCT05655312
[212Pb]Pb-PSV359	Other	Phase PHASE1	Pancreatic Ductal Adenocarcinoma	RECRUITING	NCT06710756
[203Pb]Pb-PSV359	Other	Phase PHASE1	Pancreatic Ductal Adenocarcinoma	RECRUITING	NCT06710756
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[68Ga]VMT02	Other	Phase PHASE1	Melanoma (Skin)	COMPLETED	NCT04904120
[203Pb]VMT01	Other	Phase PHASE1	Melanoma (Skin)	COMPLETED	NCT04904120
SPECT/CT	Other	Phase EARLY_PHASE1	Neuroendocrine Tumor Grade 2	ACTIVE_NOT_RECRUITING	NCT05111509
[203Pb]VMT-α-NET	Other	Phase EARLY_PHASE1	Neuroendocrine Tumor Grade 2	ACTIVE_NOT_RECRUITING	NCT05111509
[203Pb] VMT-α-NET SPECT/CT	Other	Phase EARLY_PHASE1	Neuroendocrine Tumors	ACTIVE_NOT_RECRUITING	NCT06148636
[212Pb] VMT-α-NET	Other	Phase EARLY_PHASE1	Neuroendocrine Tumors	ACTIVE_NOT_RECRUITING	NCT06148636
Nivolumab	Other	Phase PHASE1	Recurrent Melanoma (Skin)	RECRUITING	NCT05655312
[212Pb]VMT01	Other	Phase PHASE1	Recurrent Melanoma (Skin)	RECRUITING	NCT05655312
[203Pb]VMT01	Other	Phase PHASE1	Recurrent Melanoma (Skin)	RECRUITING	NCT05655312
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]Pb-PSV359	Other	Phase PHASE1	Pancreatic Ductal Adenocarcinoma	RECRUITING	NCT06710756
[203Pb]Pb-PSV359	Other	Phase PHASE1	Pancreatic Ductal Adenocarcinoma	RECRUITING	NCT06710756
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]Pb-PSV359	Other	Phase PHASE1	Pancreatic Ductal Adenocarcinoma	RECRUITING	NCT06710756
[203Pb]Pb-PSV359	Other	Phase PHASE1	Pancreatic Ductal Adenocarcinoma	RECRUITING	NCT06710756
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]Pb-PSV359	Other	Phase PHASE1	Pancreatic Ductal Adenocarcinoma	RECRUITING	NCT06710756
[203Pb]Pb-PSV359	Other	Phase PHASE1	Pancreatic Ductal Adenocarcinoma	RECRUITING	NCT06710756
[212Pb]Pb-PSV359	Other	Phase PHASE1	Pancreatic Ductal Adenocarcinoma	RECRUITING	NCT06710756
[203Pb]Pb-PSV359	Other	Phase PHASE1	Pancreatic Ductal Adenocarcinoma	RECRUITING	NCT06710756
[212Pb]Pb-PSV359	Other	Phase PHASE1	Pancreatic Ductal Adenocarcinoma	RECRUITING	NCT06710756
[203Pb]Pb-PSV359	Other	Phase PHASE1	Pancreatic Ductal Adenocarcinoma	RECRUITING	NCT06710756
[212Pb]Pb-PSV359	Other	Phase PHASE1	Pancreatic Ductal Adenocarcinoma	RECRUITING	NCT06710756
[203Pb]Pb-PSV359	Other	Phase PHASE1	Pancreatic Ductal Adenocarcinoma	RECRUITING	NCT06710756
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[212Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618
[203Pb]VMT-α-NET	Other	Phase PHASE1	Neuroendocrine Tumors Unresectable	RECRUITING	NCT05636618

Total products: 92